Nyxoah (NASDAQ:NYXH) versus Spectral AI (NASDAQ:MDAI) Financial Contrast

Nyxoah (NASDAQ:NYXH) and Spectral AI (NASDAQ:MDAI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Valuation and Earnings

This table compares Nyxoah and Spectral AI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.87)	-4.21
Spectral AI	$27.26 million	1.48	-$20.85 million	($0.65)	-3.34

Spectral AI has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nyxoah and Spectral AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
Spectral AI	-40.78%	N/A	-77.87%

Analyst Recommendations

This is a summary of current recommendations and price targets for Nyxoah and Spectral AI, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
Spectral AI	0	0	3	1	3.25

Nyxoah currently has a consensus price target of $17.00, indicating a potential upside of 116.01%. Spectral AI has a consensus price target of $4.50, indicating a potential upside of 107.37%. Given Nyxoah’s higher possible upside, research analysts clearly believe Nyxoah is more favorable than Spectral AI.

Insider & Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Nyxoah has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Summary

Spectral AI beats Nyxoah on 10 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.